Gefitinib is a small molecule inhibitor of EGFR-TK. The inhibition of EGFR-TK can inhibit tumour growth, metastasis and angiogenesis, and increase tumour cell apoptosis.
English Name: Iressa / gefitinib tables
English alias: geninib; Akos 91371; N - (3-chloro-4-fluoro-Phyl) - 7-proxy-6 - (3-morpho- 4-ylproxy) quinazolin-4-amine; N - (3-chloro- 4-ylproxy) quinazolin-4-amine; N - (3-chloro- 4-Fluorophenol) - 7-methoxy-6 - [3 - (4-morpholinyl) proxy] --4-quinazolinamine; z1839; 4-quinazolinamine, N - (3-chloro- 4-fluoro- 4-fluoro- fluopassword) - 7-metadata-4-ami; n - (3-chloro- 4-fluoro- 4-fluoro- fluoro- 4-fluorophyphyphyl) - 7-methoxy-6 - [3 - (4-chloro- 4-fluoro- 4-fluoro- 4-Fluorophenol) - 7-7-metho- 7-methohoxy-6 - [3 - (4-morpholinyl) proxy] -; gefitinib (tinibs); gefitinib, Iressa, zd18 39; gefitinib base
CAS No.: 184475-35-2
Molecular formula: c22h24clfn4o3
Molecular weight: 446.9024
Gefitinib184475-35-2 has a rapid effect, and the average medication for 8-10 days can alleviate the symptoms. If it is effective, most of them can be reflected in one month. A rash is a common adverse reaction. It should be noted that no alkaline chemical daily necessities, such as soap, should be used to clean the skin. Only water can be used. When the skin is broken or there is an abscess, pay attention to avoid infection. If necessary, ask a dermatologist for treatment. Asymptomatic moderate transaminase rise does not need to stop the drug, some patients can recover by themselves. However, if there is a moderate increase in transaminase, it is best to stop taking the medicine first, and then take the medicine again after recovery.